Journal of Clinical Oncology
Articles in this Issue
Becotatug vedotin vs. chemotherapy in pre-heavily treated advanced nasopharyngeal carcinoma: A randomized, controlled, multicenter, open-label study.
LBA6005 Background: Becotatug vedotin (MRG003) is a novel EGFR-targeted antibody-drug conjugate. Previous Phase I/II studies have demonstrated optimistic...
Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study.
LBA109 Background: Although PD-1/PD-L1 inhibitors plus chemo have expanded treatment options for previously untreated PD-L...
TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7).
LBA5500 Background: Optimal timing of cytoreduction in non-frail patients (pts) with seemingly resectable stage IIIB-IVB o...
The Genetic Information and Family Testing (GIFT) trial.
LBA10606 Background: Engaging patients with inherited cancer susceptibility is a potentially powerful strategy to reduce the gap in genetic risk evaluatio...
Safety and efficacy of reduced-port laparoscopic surgery for patients with colon and upper rectal cancer.
LBA3555 Background: Radical laparoscopic resection is the mainstay of treatments for non-metastatic colorectal cancer (CRC). Reduced-port laparoscopic sur...
Anlotinib versus bevacizumab added to standard first-line chemotherapy among patients with RAS/BRAF wild-type, unresectable metastatic colorectal cancer: A multicenter, prospective, randomised, phase 3 clinical trial (ANCHOR trial).
LBA3502 Background: Anti-VEGF antibodies combined with chemotherapy remain first-line treatment for unresectable metastatic colorectal cancer (mCRC), but...
Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent <i>ESR1</i> mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial.
LBA4 Background: ESR1 mutations ( ESR1 m) constitutively activ...
An international, multicenter, prospective randomized trial of adjuvant chemotherapy for stage Ia-IIa non-small cell lung cancer identified as high-risk by a 14-gene molecular assay.
LBA8027 Background: Despite advances in late-stage treatments, survival of early-stage non-small cell lung cancer (NSCLC) remains dismal, with 5-year dise...
Cancer Care Beyond Walls (CCBW): A randomized pragmatic trial of home-based versus in-clinic cancer therapy administration.
LBA1551 Background: Traditional cancer therapy is primarily delivered in clinical settings, imposing logistical, emotional, and financial burdens, particu...
Aspirin as secondary prevention for colorectal cancer liver metastases (ASAC): A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial.
LBA3511 Background: Approximately 50% of patients with colorectal cancer develop liver metastases, and while surgical resection improves survival, over ha...
Perioperative nivolumab (NIVO) vs placebo (PBO) in patients (pts) with resectable NSCLC: Updated survival and biomarker analyses from CheckMate 77T.
LBA8010 Background: The phase 3 CheckMate 77T study demonstrated statistically significant and clinically meaningful impro...
PRO-ACTIVE: Results of a pragmatic phase IV randomized trial comparing the effectiveness of prophylactic swallow intervention for patients receiving radiotherapy for head and neck cancer.
LBA12000 Background: Swallowing therapy during radiotherapy (RT) for head and neck cancer (HNC) has gained popularity as a dysphagia mitigation strategy,...
Primary analysis of the EORTC-2139-MG/Columbus-AD trial: A randomized trial of adjuvant encorafenib and binimetinib versus placebo in high-risk stage II melanoma with a BRAF-V600E/K mutation.
LBA9501 Background: Resected stage IIB/IIC melanoma has a high risk of recurrence. While, for decades, surgery was the only option for high-risk stage II...
Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC).
LBA5 Background: FLOT is a perioperative standard of care (SoC) in resectable GC/GEJC, yet recurrence rates remain high. Immune checkpoint inhibitors are...
Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (C)/trastuzumab (Tra) as first-line (1L) treatment of patients (pts) with HER2-expressing locally advanced or metastatic (la/m) gastric cancer.
LBA4012 Background: DV+T showed encouraging efficacy with manageable safety for pts with HER2-expressing gastric or gastroesophageal junction (G/GEJ) canc...
A randomized phase III trial of the impact of a structured exercise program on disease-free survival (DFS) in stage 3 or high-risk stage 2 colon cancer: Canadian Cancer Trials Group (CCTG) CO.21 (CHALLENGE).
LBA3510 Background: Multiple observational studies have reported that post-diagnosis physical activity (PA) is associated with reduced recurrence rates in...
JMT101 in combination with irinotecan and SG001 versus regorafenib in patients with metastatic colorectal adenocarcinoma (mCRC): Results of a randomized, controlled, open-label, phase II study.
LBA3516 Background: Both Becotatug (JMT101, humanized IgG1 anti-EGFR monoclonal antibody [mAb]) ± chemotherapy, and Enlonstobart (SG001, humanized IgG4 an...
Randomized phase II trial investigating whether atezolizumab after chemoradiotherapy (CRT) prolongs survival in limited stage (LS) small cell lung cancer (SCLC).
LBA8005 Background: A majority of patients with LS SCLC relapse after potentially curative CRT and better treatment is needed. Immunotherapy prolongs surv...
Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC).
LBA1 Background: Standard adjuvant chemotherapy of stage III colon cancer consists of a fluoropyrimidine plus oxaliplatin....
R-ALPS: A randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of TQB2450 with or without anlotinib as maintenance treatment in patients with locally advanced and unresectable (stage III) NSCLC without progression following concurrent or sequential chemoradiotherapy.
LBA8004 Background: Benmelstobart (TQB2450) is a novel humanized IgG1 monoclonal antibody targeting programmed death-ligand 1 (PD-L1). Anlotinib, a multi-...
Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.
LBA5504 Background: Prior results from ENGOT-cx11/GOG-3047/KEYNOTE-A18 (NCT04221945) showed that pembro + CCRT and then continued after CCRT provided stat...
The phase II NIBIT-ML1 study of nivolumab plus ipilimumab and ASTX727 or nivolumab plus ipilimumab in PD-1 resistant metastatic melanoma: Tumor methylation landscape and correlation with clinical outcomes.
LBA2512 Background: In the NIBIT Foundation-sponsored phase Ib NIBIT-M4 study, we firstly showed that the hypomethylating...
De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): A multicentre, open-label, randomised, phase 3 trial.
LBA500 Background: Neoadjuvant taxane, carboplatin and trastuzumab plus pertuzumab is associated with excellent treatment...
Results from VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV).
LBA3 Background: PV is characterized by red blood cell overproduction. Rusfertide is a subcutaneous (SC), self-injected, first-in-class peptide hepcidin m...
NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.
LBA2 Background: The standard of care (SOC) over the past two decades for resected locally advanced SCCHN (LA-SCCHN) with high-risk of relapse is adjuvant...